AC
IMUC

Armistice Capital’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Armistice Capital’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-61,788
Closed -$1.2M – 39
2015
Q1 		$1.2M Buy
+61,788
New +$1.55M 0.53% 25

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Armistice Capital's IMUC Position: Q2 2015 in Review

Armistice Capital sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2015, closing a stake of 61,788 shares — an estimated $1.2M sold.

Armistice Capital first reported a position in IMUC in Q1 2015 and held it in 1 quarter. The position peaked at $1.2M in Q1 2015. 31 funds tracked by Wall St. Rank hold IMUC as of Q2 2015.

  • Armistice Capital reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q2 2015 after selling out during the quarter.
  • Armistice Capital sold 61,788 ImmunoCellular Therapeutics, Ltd. shares in Q2 2015, an estimated $1.2M.
  • Armistice Capital first reported a position in ImmunoCellular Therapeutics, Ltd. in Q1 2015 and held it in 1 quarter.
  • Armistice Capital's ImmunoCellular Therapeutics, Ltd. position peaked at $1.2M in Q1 2015.
  • 31 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2015.

Based on Armistice Capital's 13F filing for Q2 2015, filed 14 Aug 2015.